Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00674011 · ClinicalTrials.gov registry record
Hypertension in Breast Cancer Patients Receiving Bevacizumab
A clinical trial, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- 10
- Enrollment target
NCT00674011: Clinical Trial study, sponsored by Dana-Farber Cancer Institute.
NCT00674011 is a clinical trial that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00674011 was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- 10 participants
- Enrollment target
Study Summary
This research study will look at the effect of an anti-angiogenesis medication called Bevacizumab on blood vessels. Anti-angiogenesis medicines fight cancer by cutting off a tumor's blood supply, starving the tumor of nutrients and oxygen. Previous studies have shown these types of drugs can cause hypertension. The purpose of this study is to help researchers better understand why these drugs cause hypertension. This information will assist researchers in learning how to control this side effect.
Interventions
- DRUG Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-09 |
Why NCT00674011 stopped before completion
NCT00674011 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Bevacizumab is the first listed.
NCT00674011 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00674011 about?
NCT00674011 is a clinical study titled "Hypertension in Breast Cancer Patients Receiving Bevacizumab". This research study will look at the effect of an anti-angiogenesis medication called Bevacizumab on blood vessels. Anti-angiogenesis medicines fight cancer by cutting off a tumor's blood supply, starving the tumor of nutrients and oxygen. Previous studies have shown these types of drugs can cause h...
What is the current status of trial NCT00674011?
This trial is currently terminated. The enrollment target is 10 participants. The study started on 2008-01. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00674011?
The interventions under investigation include: Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00674011?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia